- Home
- PROK vs BNY Comparison
PROK vs BNY Comparison
Compare PROK & BNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- BNY
- Stock Information
- Founded
- PROK 2015
- BNY 2001
- Country
- PROK United States
- BNY United States
- Employees
- PROK 163
- BNY N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- BNY Trusts Except Educational Religious and Charitable
- Sector
- PROK Health Care
- BNY Finance
- Exchange
- PROK Nasdaq
- BNY Nasdaq
- Market Cap
- PROK 212.4M
- BNY 246.8M
- IPO Year
- PROK N/A
- BNY N/A
- Fundamental
- Price
- PROK $1.66
- BNY $10.30
- Analyst Decision
- PROK Buy
- BNY
- Analyst Count
- PROK 5
- BNY 0
- Target Price
- PROK $4.50
- BNY N/A
- AVG Volume (30 Days)
- PROK 566.3K
- BNY 52.7K
- Earning Date
- PROK 11-12-2024
- BNY 01-01-0001
- Dividend Yield
- PROK N/A
- BNY 3.93%
- EPS Growth
- PROK N/A
- BNY N/A
- EPS
- PROK N/A
- BNY N/A
- Revenue
- PROK N/A
- BNY N/A
- Revenue This Year
- PROK N/A
- BNY N/A
- Revenue Next Year
- PROK N/A
- BNY N/A
- P/E Ratio
- PROK N/A
- BNY N/A
- Revenue Growth
- PROK N/A
- BNY N/A
- 52 Week Low
- PROK $1.18
- BNY $8.60
- 52 Week High
- PROK $4.44
- BNY $10.80
- Technical
- Relative Strength Index (RSI)
- PROK 46.29
- BNY 46.21
- Support Level
- PROK $1.50
- BNY $10.18
- Resistance Level
- PROK $1.90
- BNY $10.28
- Average True Range (ATR)
- PROK 0.15
- BNY 0.09
- MACD
- PROK -0.01
- BNY 0.01
- Stochastic Oscillator
- PROK 45.45
- BNY 61.85
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.